{"id":32692,"date":"2025-04-09T12:26:22","date_gmt":"2025-04-09T10:26:22","guid":{"rendered":"https:\/\/ggba.swiss\/?p=32692"},"modified":"2025-04-09T12:26:23","modified_gmt":"2025-04-09T10:26:23","slug":"novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/","title":{"rendered":"Novigenix secures EUR 1.8 million to scale precision oncology platform"},"content":{"rendered":"\n

Novigenix<\/a>, a company based at Biop\u00f4le<\/a> in Lausanne and specializing in AI-powered precision oncology, has been awarded EUR 1.8 million through the European Union\u2019s Innovative Health Initiative (IHI<\/a>). The funding supports its participation in BRECISE, a pan-European research consortium aiming to transform cancer diagnostics and treatment through the integration of next-generation sequencing (NGS) and artificial intelligence.<\/p>\n\n\n\n

BRECISE was officially launched in Madrid during the European Association of Urology Congress and brings together partners from academia, clinical institutions, and industry. Co-funded under Horizon Europe, the initiative focuses on accelerating the validation of biomarker models to support more personalized and effective cancer care, with a particular focus on prostate and bladder cancers.<\/p>\n\n\n\n

Strengthening Europe\u2019s innovation ecosystem in cancer care<\/h4>\n\n\n\n

As part of the project, Novigenix will advance its LITOSeek platform, a liquid biopsy technology that combines transcriptomic and genomic data derived from blood samples. Using AI-based analytics, LITOSeek aims to improve the prediction of patient response to immunotherapies, identify potential adverse effects, and support biopharma companies in optimizing patient selection for clinical trials. These capabilities could lead to more effective treatments while reducing complications and inefficiencies in drug development.<\/p>\n\n\n\n

The grant will allow Novigenix to move from research-scale development toward industrialization, ensuring the platform meets the standards required for clinical adoption across European healthcare systems. The company\u2019s contribution reflects over a decade of expertise in multi-omics data integration and AI-driven diagnostics.<\/p>\n\n\n\n

By participating in BRECISE, Novigenix reinforces Western Switzerland\u2019s presence in European innovation ecosystems and underlines the strategic importance of cross-border collaboration in advancing precision medicine. The project demonstrates how emerging technologies can bring tangible improvements to patient care and contribute to the evolution of oncology across Europe.<\/p>\n","protected":false},"excerpt":{"rendered":"

Medtech start-up Novigenix has received EUR 1.8 million from the EU\u2019s Innovative Health Initiative to support the industrialization of its AI-driven liquid biopsy platform as part of a major international cancer research collaboration.<\/p>\n","protected":false},"author":6,"featured_media":32693,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[893,956,912,894,890,883],"class_list":["post-32692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-artificial-intelligence","tag-biometrics","tag-biotech","tag-financing","tag-healthcare","tag-oncology"],"acf":[],"yoast_head":"\nNovigenix secures EUR 1.8M to scale precision oncology platform<\/title>\n<meta name=\"description\" content=\"Novigenix has received EUR 1.8 million to support the industrialization of its AI-driven liquid biopsy platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novigenix secures EUR 1.8M to scale precision oncology platform\" \/>\n<meta property=\"og:description\" content=\"Novigenix has received EUR 1.8 million to support the industrialization of its AI-driven liquid biopsy platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T10:26:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-09T10:26:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Novigenix secures EUR 1.8 million to scale precision oncology platform\",\"datePublished\":\"2025-04-09T10:26:22+00:00\",\"dateModified\":\"2025-04-09T10:26:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/\"},\"wordCount\":289,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\",\"keywords\":[\"Artificial Intelligence\",\"Biometrics\",\"Biotech\",\"Financing\",\"Healthcare\",\"Oncology\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/\",\"url\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/\",\"name\":\"Novigenix secures EUR 1.8M to scale precision oncology platform\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\",\"datePublished\":\"2025-04-09T10:26:22+00:00\",\"dateModified\":\"2025-04-09T10:26:23+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Novigenix has received EUR 1.8 million to support the industrialization of its AI-driven liquid biopsy platform.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Based at Lausanne\u2019s Biop\u00f4le campus, Novigenix is contributing to the EU-funded BRECISE project with its predictive liquid biopsy technology. | \u00a9 Novigenix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novigenix secures EUR 1.8 million to scale precision oncology platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novigenix secures EUR 1.8M to scale precision oncology platform","description":"Novigenix has received EUR 1.8 million to support the industrialization of its AI-driven liquid biopsy platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/","og_locale":"en_US","og_type":"article","og_title":"Novigenix secures EUR 1.8M to scale precision oncology platform","og_description":"Novigenix has received EUR 1.8 million to support the industrialization of its AI-driven liquid biopsy platform.","og_url":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-04-09T10:26:22+00:00","article_modified_time":"2025-04-09T10:26:23+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Novigenix secures EUR 1.8 million to scale precision oncology platform","datePublished":"2025-04-09T10:26:22+00:00","dateModified":"2025-04-09T10:26:23+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/"},"wordCount":289,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","keywords":["Artificial Intelligence","Biometrics","Biotech","Financing","Healthcare","Oncology"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/","url":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/","name":"Novigenix secures EUR 1.8M to scale precision oncology platform","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","datePublished":"2025-04-09T10:26:22+00:00","dateModified":"2025-04-09T10:26:23+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Novigenix has received EUR 1.8 million to support the industrialization of its AI-driven liquid biopsy platform.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","width":1180,"height":811,"caption":"Based at Lausanne\u2019s Biop\u00f4le campus, Novigenix is contributing to the EU-funded BRECISE project with its predictive liquid biopsy technology. | \u00a9 Novigenix"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Novigenix secures EUR 1.8 million to scale precision oncology platform"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/32692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=32692"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/32692\/revisions"}],"predecessor-version":[{"id":32696,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/32692\/revisions\/32696"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/32693"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=32692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=32692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=32692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}